Today: 21 May 2026
IonQ stock today: IONQ edges lower in year-end session as South Korea quantum deal stays in focus
31 December 2025
2 mins read

IonQ stock today: IONQ edges lower in year-end session as South Korea quantum deal stays in focus

NEW YORK, December 31, 2025, 2:57 PM ET — Regular session

  • IonQ shares were down 0.1% at $45.26 in afternoon trading, lagging a cautious year-end tape.
  • Investors have been tracking quantum-computing names closely as thin holiday liquidity can amplify moves.
  • IonQ’s latest company update highlighted a planned 100-qubit system delivery to South Korea’s KISTI.

IonQ, Inc. shares dipped in afternoon trading on Wednesday as investors navigated the final session of the year with light volumes and a cautious tone. The stock was down 0.1% at $45.26.

The muted move matters because IonQ sits in a small group of quantum-computing stocks that have been prone to sharp swings on headlines, with year-end positioning often exaggerating daily price action.

Risk appetite was already fragile as U.S. stocks slipped in holiday-thin trading, with technology weighing on the broader market even as the main indexes remained on track for annual gains.

The latest company catalyst came earlier this week when IonQ said it finalized an agreement with South Korea’s Korea Institute of Science and Technology Information (KISTI) and would deliver a 100-qubit IonQ Tempo quantum system. “This is a defining moment for both IonQ and South Korea,” Chairman and CEO Niccolo de Masi said. IonQ Investors

A qubit is the basic unit of information in quantum computing. In simple terms, more qubits can increase the size of problems a quantum machine can work on, though performance also depends on error rates and how well systems run reliably.

IonQ said the system will be integrated into KISTI-6, a high-performance computing (HPC) cluster — essentially a large, tightly connected supercomputing environment — in what the company described as the country’s first onsite hybrid quantum-classical integration. IonQ said users will be able to access the platform remotely through a secure private cloud.

Other quantum-computing stocks were mixed on the day, underscoring the sector’s headline-driven churn. D-Wave Quantum rose 1.4%, while Rigetti Computing fell 0.9% and Quantum Computing Inc slipped 0.4%.

Macro data also set the backdrop for growth stocks. U.S. weekly jobless claims fell unexpectedly to 199,000, according to Labor Department data, a report published a day early ahead of the New Year’s holiday.

The next major labor-market checkpoint is the December employment report due on January 9, which investors will use to reassess the outlook for interest rates.

IonQ’s shares have pulled back sharply from late-December levels, reflecting the volatility that has defined the quantum-computing trade. The stock is down about 16% from its Dec. 22 close, based on daily pricing data.

Traders are watching whether IonQ can regain momentum above the mid-$40s while the company works through delivery timelines and customer adoption of new systems, a key proof-point for revenue conversion in early-stage quantum businesses.

Wall Street also has an eye on the next earnings cycle. Zacks projects IonQ’s next earnings release around Feb. 25, though timing can shift as companies set their calendars.

For now, with year-end volumes thin, IonQ’s day-to-day direction is likely to hinge on risk sentiment and any incremental updates that show contract announcements turning into deployed systems and recurring usage.

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious
Previous Story

AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop